2016 WHO classification incorporate IDH mutation and 1p/19q codeletion status to further classified WHO II/III glioma into three molecular subtypes: IDH‐wildtype, IDH‐mutant and 1p/19q intact, and IDH‐mutant and 1p/19q codeleted.3 This evidence concerns the gene IDH1 and central nervous system cancer.